- Research article
- Open Access
The release and trans-synaptic transmission of Tau via exosomes
Molecular Neurodegeneration volume 12, Article number: 5 (2017)
Tau pathology in AD spreads in a hierarchical pattern, whereby it first appears in the entorhinal cortex, then spreads to the hippocampus and later to the surrounding areas. Based on this sequential appearance, AD can be classified into six stages (“Braak stages”). The mechanisms and agents underlying the progression of Tau pathology are a matter of debate. Emerging evidence indicates that the propagation of Tau pathology may be due to the transmission of Tau protein, but the underlying pathways and Tau species are not well understood. In this study we investigated the question of Tau spreading via small extracellular vesicles called exosomes.
Exosomes from different sources were analyzed by biochemical methods and electron microscopy (EM) and cryo-EM. Microfluidic devices that allow the culture of cell populations in different compartments were used to investigate the spreading of Tau.
We show that Tau protein is released by cultured primary neurons or by N2a cells overexpressing different Tau constructs via exosomes. Neuron-derived exosomal Tau is hypo-phosphorylated, compared with cytosolic Tau. Depolarization of neurons promotes release of Tau-containing exosomes, highlighting the importance of neuronal activity. Using microfluidic devices we show that exosomes mediate trans-neuronal transfer of Tau depending on synaptic connectivity. Tau spreading is achieved by direct transmission of exosomes between neurons. In organotypic hippocampal slices, Tau-containing exosomes in conditioned medium are taken up by neurons and microglia, not astrocytes. In N2a cells, Tau assemblies are released via exosomes. They can induce inclusions of other Tau molecules in N2a cells expressing mutant human Tau. We also studied exosomes from cerebrospinal fluid in AD and control subjects containing monomeric and oligomeric Tau. Split-luciferase complementation reveals that exosomes from CSF can promote Tau aggregation in cultured cells.
Our study demonstrates that exosomes contribute to trans-synaptic Tau transmission, and thus offer new approches to control the spreading of pathology in AD and other tauopathies.
Tau aggregates are one of the hallmarks of Alzheimer disease (AD) . In AD, the distribution of Tau aggregates correlates with the severity of dementia and occurs in a hierarchical pattern, whereby it first appears in the entorhinal cortex, then spreads to the hippocampus and later to the surrounding areas . Based on this sequential appearance, AD can be classified into 6 stages . Up to date, the mechanism underlying the progression of Tau pathology remains elusive. It has become of major interest, as blocking the propagation of Tau pathology might represent a promising therapeutic strategy for AD and other tauopathies.
In AD, neurons prone to develop NFTs are projection neurons with long axons that are only poorly myelinated . This led to the assumption that these neurons are intrinsically vulnerable to Tau pathology, because they have high energy requirements (that is, high metabolic rates) that may subject them to chronic oxidative stress . In addition their poor myelination increases their exposure to toxic environmental conditions, as myelin sheaths provide a mechanical barrier against pathogens and provide trophic support and protection against oxidative stress . On the other hand, neurons affected by Tau pathology appear to be anatomically connected . Thus, it is not clear whether the spread of Tau pathology is due to their neuronal connectivity or due to the differential vulnerability of neurons to Tau pathology. Emerging evidence supports the former proposal. Several recent studies showed that inoculation of Tau aggregates induces time-dependent spreading of Tau pathology from the inoculation site to synaptically connected brain regions in human Tau transgenic mice or even in wild type mice. In two lines of Tau transgenic mice, the expression of human Tau under the control of the neuropsin promoter was restricted to the entorhinal cortex, yet Tau aggregates composed of transgenic human Tau and endogenous mouse Tau were detected in brain regions downstream in the synaptic circuit such as the dentate gyrus, CA fields of the hippocampus, and cingulate cortex [8, 9]. Since no expression of human Tau was detected in these regions, human Tau in these areas should derive from the entorhinal cortex. Taken together, these studies indicate that Tau may be transmitted between neurons by a trans-synaptic pattern. However, the mechanism of transmission remains a matter of debate.
Tau is a microtubule associated protein and as such is primarily an intracellular protein. However, several recent studies showed that Tau can be physiologically released to the extracellular fluid both in vivo and in cultured cells, and such release appears to be regulated by neuronal activity [10–13]. So far, the physiological function of extracellular Tau remains elusive. In vitro and in vivo studies showed that exogenous Tau aggregates can be internalized by neurons and act as seeds to induce the aggregation of other Tau proteins [14–17]. Based on these findings, it has been proposed that the release and uptake of Tau underlies the spreading of Tau pathology . However, how and what Tau species are released by donor neurons and then taken up by recipient neurons is not clear.
Exosomes are small extracellular vesicles with a diameter of 50–150 nm, which derive from multivesicular endosomes fusing with the plasma membrane [19, 20]. Secreted exosomes can be taken up by and thus deliver their content to the recipient cells  thus representing a novel intercellular communication pathway. Exosomes can be released at neuronal presynaptic terminals and taken up by postsynapses at Drosophila neuromuscular junctions (NMJ) , and therefore qualify as carriers for trans-synaptic transmission of proteins. Therefore, it is reasonable to assume that exosomes might be involved in the trans-synaptic spreading of Tau pathology. It has been reported that α-synuclein, prion protein and β-amyloid are present in exosomes [23–25], but whether or not Tau is a component of exosomes is still a matter of debate. Several studies showed that exosomes isolated from the conditioned medium of cultured cell lines over-expressing Tau or CSF from AD patients indeed contain Tau [26–28], while other studies reported that no Tau was detected in exosomes isolated from conditioned medium of cultured primary neurons or cell lines [12, 29]. Thus, more investigation is needed to clarify this issue.
In the current study, we determined that Tau is a bona fide component of exosomes. We characterized the Tau species secreted in association with exosomes from cultured neurons or human CSF from AD or control subjects. Using microfluidic devices we showed that exosomes play a role in the neuron-to-neuron transmission of Tau. Finally, we found that exosomes could mediate the propagation of Tau aggregation between cells.
Antibodies and chemicals
Mouse monoclonal antibodies against Alix/AIP1 and Flotillin-1 were purchased from BD Biosciences (Heidelberg, Germany). Rabbit polyclonal antibody K9JA was purchased from Dako (Dako, Glostrup, Denmark). Phosphorylation-dependent monoclonal mouse antibody PHF1 (against pS396 + pS404) was a gift from Peter Davies (Albert Einstein College, Bronx, NY, USA); 12E8 (against pS262 and pS356) was from Peter Seubert (Elan Pharmaceuticals, South San Francisco, CA, USA); AT8 (against pS202 + pT205) and AT180 (against pT231) were from Pierce (Thermo, Fisher Scientific, Bonn, Germany). Antibody against GluR1 was purchased from Millipore (Darmstadt, Germany). Thioflavine S and antibody against synaptophysin was obtained from Sigma (Steinheim, Germany).
Cell culture, transfection and treatments
The inducible Tet-On mouse neuroblastoma cells (N2a) expressing the 4-repeat domain of Tau or full-length Tau harboring the FTDP-17 mutation ΔK280 was generated as previously described . The cells were cultured in Eagle’s Minimum Essential Medium (MEM) supplemented with 10% exosome-depleted fetal bovine serum (FBS), 0.1% nonessential amino acids, and 600 μg/ml G418. The exosome-depleted FBS was prepared by centrifugation at 100,000 × g for 1 h. The expression of Tau was induced with 1 μg/ml doxycycline.
Cortical neurons were isolated from Sprague-Dawley rat embryos at Day 18 (E18) and seeded on poly-D-lysine-coated (50 μg/mL) dishes. The cultures were kept for 4 h in plating medium (MEM, 10% horse serum albumin (no tau was detected in exosomes isolated from 50 ml horse serum, data not shown), 1 mM pyruvic acid, 0.6% glucose, 1× penicillin/streptavidin) and then the medium was exchanged to NeuroBasal medium supplemented with B27 (Invitrogen, Carlsbad, CA, USA), L-Glutamine and Penicillin/Streptomycin. Four days after seeding, cytosine arabinoside (Sigma, Munich, Germany) was added to the conditional medium at a final concentration of 5 μg/ml to inhibit the glial proliferation.
For neuronal culture in microfluidic devices (Xona microfluidics, USA), hippocampal neurons isolated from Sprague-Dawley rat embryos at Day 18 (E18) were seeded at a density of ~6 × 104 cells on one side (somal side). Two weeks later, the other side of the microfluidic devices (neuritic side) was seeded with hippocampal neurons at a density of ~3 × 104 cells. The neurons were cultured as described above.
When the neurons on the somal side of the microfluidic devices reached the age of DIV18 or DIV25, 60 μl of conditioned medium in each well on the somal side was removed and then 10 μl of purified exosomes re-suspended in conditioned medium was added to each of the two wells for 24 h.
Transfections of N2a cells with GFP-Tau construct (human Tau tagged with GFP at the N-terminus (longest isoform in CNS, 2N4R or hTau40, for short TauGFP)) or with GFP-Flotillin (FlotillinGFP) and the RFP-Tau construct (human Tau tagged with RFP at the N-terminus (longest isoform in CNS, 2N4R or hTau40, for short TauRFP)) were performed with lipofectamine 2000 (Invitrogen) according to manufacturer’s manual. Twenty-four hours later, the conditioned medium was removed, and the cells were washed with warm PBS and split into new flasks. Cortical neurons were infected with adeno-virus expressing the same Tau construct tagged with CFP at the N-terminus (TauCFP).
Cytotoxicity was determined by a lactate dehydrogenase (LDH) assay kit (Roche Applied Science, Indianapolis, USA) according to manufacturer’s manual. Cell death was calculated as percent of LDH released into the medium, compared with total LDH obtained.
Organotypic hippocampal slice culture and treatments
Hippocampal organotypic slice cultures were prepared from non-transgenic P8 mice and cultured as described previously . At 15 DIV, 200 μl of a GFP-hTau40-exosome-preparation was applied to the medium of organotypic slice cultures for 24 h at 37 °C/5%CO2 atmosphere. As a control, 200 μl of the same exosome preparation was sonicated before application.
Purification of exosomes
Exosomes were purified from conditioned medium of N2a cells or cultured cortical neurons (DIV14-21) as described . Briefly, conditioned medium was collected from 10 to 16 dishes (150 mm) of neurons at a density of 1.5 × 107 cells/dish or from nine T150 flasks of N2a cells at a density of 2–2.5 × 107 cells/flask. The collected medium was centrifuged at 300 × g for 10 min to remove cells. The supernatant was then sequentially centrifuged at 2000 × g for 10 min to remove dead cells and at 10,000 × g for 30 min to remove cell debris. Afterwards, the supernatant was collected and centrifuged at 100,000 × g for 70 min. The pellet (exosomes + contaminating proteins) was washed with PBS to eliminate contaminated proteins and centrifuged at 100,000 × g for 70 min to collect purified exosomes. The exosomes were then used for treatment of N2a cells or cultured primary neurons.
For sucrose gradient centrifugation, the 100,000 × g pellet was resuspended in 2.5 M sucrose in 20 mM Hepes (pH 7.4), and a step gradient of sucrose (2.25, 2.0, 1.75, 1.5, 1.25, 1.0, 0.75, 0.5, and 0.25 M) was layered over the exosome-containing 2.5 M sucrose solution as described . The gradient was spun at 100,000 × g for 18 h. Fractions were collected from the bottom of the gradient, diluted with PBS, and spun at 100,000 × g for 2 h. The pelleted fractions were then used for immunoblotting.
The sonication of exosomes was done with a Sonoplus Ultrasonic homogenizer (Bandelin, Berlin, Germany) using 20% amplitude for 10s.
Human CSF collection
Lumbar CSF of patients with AD and from psychiatric controls was collected with an atraumatic needle at the Department of Psychiatry, University Medical Center, Göttingen, Germany after written informed consent was obtained (IRB 02/05/09). All performed analyses with human CSF were approved by the ethics committee of the Medical Faculty, University Medicine Göttingen (IRB 02/05/09). Specimens were collected in polypropylene tubes and centrifuged at 2,000xg for 10 min at room temperature, aliquoted and frozen at −80 °C within 30 min of the procedure’s completion.
All AD patients fulfilled the NINCDS-ADRDA diagnosis criteria for probable AD . Patients were extensively characterized by the memory clinic’s expert physicians and neuropsychologists including physical, neurological, psychiatric and neuropsychological examination, brain imaging as well as CSF Abeta 42, Tau and phospho-Tau analysis. Controls included CSF from patients with different psychiatric diagnoses (overview in Tables 1 and 2). None of the control patients suffered from neurodegenerative disorders or dementia. Only CSF samples with normal routine parameters were used.
Purification of extracellular vesicles (EVs) from CSF
EVs were isolated as described previously [23, 34]. In brief, 2 ml of CSF were subjected to subsequent centrifugation steps performed at 4 °C, 3,500 × g for 10 min, 2 times 4500 × g for 10 min, 10,000 × g for 30 min and 100,000 × g for 60 min. The 100,000 × g pellet was washed once with PBS and then re-suspended in PBS.
Nanoparticle tracking analysis (NTA)
NTA was performed with a NanoSight NS300 (NanoSight Ltd., Amesbury, UK) or a Zetaview instrument (ParticleMetrix Ltd., Meerbusch, Germany). The purified exosomes were diluted 1:100–1:500 (conditioned cell medium) or 1:4 in PBS and subjected to NTA. Samples were measured in triplicates. Particle numbers were analyzed with the Nanoparticle Tracking Analysis (NTA) 3.0 software (for Nanosight NS300) or with the Zetaview 8.02.30.02.
Flow cytometry were performed on a Gallios flow cytometer (Beckman Coulter) equipped with a 22 mW blue laser operating at 488 nm. The enhanced wide forward scatter detector mode (1–19° angles with log amplification) was used to detect the microparticles in conditioned medium. Thirty microliter of conditioned medium containing exosomes was diluted into 1 ml with PBS and then measured on the FITC channel with a flow-rate of 30 μl/min. The instrument was allowed to count to a maximum of 20,000 events or 300 s, whichever was earlier without gating.
Atomic force microscopy (AFM)
The exosomal samples were diluted in PBS, and then loaded on the freshly cleaved mica for 15 min, followed by rinsing in imaging buffer (10 mm Tris-HCl, pH 7.4, 50 mm KCl). AFM imaging was performed in oscillation mode using a Nano Wizard Ultra-speed AFM microscope (JPK instruments) and Si3N4 cantilevers (NPS series, Bruker) with spring constants of 0.1–0.6 N/m. To achieve minimal imaging forces between AFM stylus and sample, the drive amplitude was set between 0.5 and 1.0 V, and the amplitude set point was adjusted manually to compensate for the thermal drift of the AFM. The acquired images were processed using JPK data processing software. The height analysis was performed using the cross section method in the JPK software.
Transmission (Cryo-) electron microscopy and tomography
Transmission electron microscopy (TEM) was done as described previously . In brief, exosomes derived from N2a cells or cortical neurons were fixed with 2% PFA and incubated for 20 min on carbon/formvar coated 200 meshes grids. The grids were then washed with PBS for 3 times and treated with 1% glutaraldehyde for 5 min. Afterwards, the grids were embedded in 2% methylcellulose; negative stained with 2% uranyl acetate and analyzed with a Philips CM12 electron microscope (Amsterdam, Netherlands).
For cryo-EM, exosomes were vitrified by plunge freezing (Leica EM GP). In brief, exosomes derived from N2a-cells (expressing TauRDΔK280 or TauGFP) or derived from neuronal cells were loaded onto holey carbon grids (200 mesh, Quantifoil, Germany), followed by plunge-freezing at 95% humidity and 25 °C. The state of vitreous water in the frozen samples was verified by electron diffraction.
Cryo-electron tomograms were recorded using a JEOL JEM2200 FS (Figs. 4 and 7) and a FEI Titan Krios (Fig. 1) cryo-Transmission electron microscope at low dose conditions. Tomograms were recorded at magnifications of 14,000x (FEI) and 20,000x (JEOL) corresponding to pixel sizes of 0.5 nm at specimen level, with a defocus of −4 to −6 nm. Samples were tilted from −60 to +60 with tilt increments of 2 or 3° steps, resulting at a total dose of 60–70 e/Å2. Tomograms were recorded using serialEM [35, 36]. Tomograms were aligned with respect to a common origin using cross-correlation techniques using the software IMOD . Reconstructions were generated using the Simultaneous Iterative Reconstruction Technique (SIRT) algorithms, and isosurface visualization was performed by the 3dmod software which is part of the IMOD software suite.
Proteinase K protection assay and high salt treatment of exosomes
The neuron-derived exosomes were divided into 30 μl aliquots and then were either left untreated or treated with 1% saponin, 50 ng proteinase K (prot K) or 50 ng proteinase K together with 1% saponin. The samples were incubated for 5 min or 1 h at 37 °C. SDS loading buffer was then added and the samples were heated at 95 °C for 5 min and analyzed by western blotting.
To dissociate extra-vesicle Tau in association with exosomal surface, the neuron-derived exosomes were incubated with increasing amounts of NaCl (0 M, 0.01 M, 0.1 M, 0.25 M or 0.5 M). Afterwards, exosomes were collected by centrifugation at 100,000 × g, 4 °C for 70 min, then resuspended in SDS loading buffer. The samples were heated to 95 °C for 5 min and analyzed by western blotting.
Luciferase protein-fragment complementation assay
Complementation pairs of TauRDΔK-N terminus of luciferase and TauRDΔK –C terminus of Luciferase were transfected into N2a cells in a T25 flask as described above. Three hours after transfection the cells were washed, trypsinated and placed into 96-well plates at a density of 15,000 cells/well. One hour later, the cells were treated with exosomes from human CSF or PBS. Forty-eight hours after treatment, the cells were treated with luciferin for 10 min and then subjected to luciferase activity measurement using an Ivis Lumina II system (Caliper Life Science).
N2a cells were fixed with 3.7% paraformaldehyde in phosphate buffered saline (PBS) for 15 min at room temperature and then permeabilized with 80% methanol for 6 min at −20 °C. Thioflavine S staining and labeling of Tau was done as described previously . For optical analysis a confocal microscope was used (LSM510, Zeiss, Oberkochen, Germany).
For immunofluorescence of neurons cultured in microfluidic devices, after treatment with exosomes, the chambers were removed and the neurons were fixed with 3.7% Formaldehyde (Sigma)/4% Sucrose in PBS for 30 min at 37 °C. After washing with PBS three times, the cells were permeabilized with 0.1% Triton X-100 for 10 min at room temperature and then blocked in 5% bovine serum albumin (BSA) for 1 h at room temperature, followed by incubation with the primary and secondary antibodies. Confocal images were captured with a LSM700 microscope (Zeiss, Oberkochen, Germany).
Organotypic hippocampal slice cultures were attached on the Millicell membrane and stained as free-floating sections in 6-well plates. Cultures were first fixed with 3.7% paraformaldehyde in PBS for 2 h at 4 °C. After washing with PBS, slices were permeabilized with 0.1% TritonX-100/PBS for 90 min at room temperature. Slices were then blocked with 5% BSA for 2 h, followed by incubation with primary antibodies diluted in PBS for 3 days at 4 °C. After washing three times with PBS, slices were incubated with secondary antibody for 3 days at 4 °C. Afterwards, slices were washed three times with PBS and then mounted with Permafluor mounting solution (Beckman Coulter, Paris, France). The following primary antibodies were used: microtubule associated protein 2a/b (MAP2a/b) (Abcam, 1:1000)), GFAP (Sigma-Aldrich, Germany; (1:1000)) and Iba1 (Wako, Japan 1:500). All fluorescently labeled secondary antibodies were from Dianova (Hamburg, Germany) (1:1000).
Enzyme-linked immunosorbent assay (ELISA)
The levels of Tau in neuron-derived exosomes and conditioned medium of neuronal culture were determined by a commercially available validated ELISA kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. All the samples were treated with 1% CHAPS detergent.
After washing twice with cold PBS, neurons or N2a cells were extracted with extraction buffer (50 mM Tris-HCl, pH 7.5; 100 mM NaCl, 1% Triton X-100 supplemented with phosphatase inhibitors and protease inhibitors). Purified exosomes were extracted with extraction buffer. Afterwards, the extracts were centrifuged at 4 °C at 16,000 × g for 20 min, and the supernatants were collected for western blot analysis.
Soluble and insoluble Tau protein was separated by sarkosyl extraction as described previously . For extraction of N2a cells, the sarkosyl-insoluble pellets were suspended in sample buffer in 1/20 of the volume of supernatants, and the sarkosyl insoluble pellets and supernatants were loaded at 60:1 (pellet:supernatant) for western blotting. For extraction of exosomes, the sarkosyl-insoluble pellets were suspended in sample buffer in 1/3 of the volume of supernatants, and the sarkosyl insoluble pellets and supernatants were loaded at 9:1 (pellet:supernatant) for western blotting. Electrophoresis and western blotting were done as described previously . For quantification of Tau levels, the western blots were probed with the pan-Tau antibody K9JA and analyzed by densitometry.
Statistical analysis was performed with the statistics software Prism5 (GraphPad, La Jolla, CA, USA). Data was analyzed either by Student’s t-test or One way ANOVA followed by Tukey’s multiple repeat comparison (Statistica, Statsoft (Europe), Hamburg, Germany) as indicated. Data are shown as mean ± SD or mean ± SEM. p-values are as follows:* < 0.05, ** < 0.01, *** < 0.001.
The release of Tau via exosomes by cultured cortical neurons
Primary neurons have been shown to release exosomes  and recent studies demonstrated the secretion of Tau by different cell lines and neurons [11, 12]. Thus we sought to determine whether Tau protein can be released via exosomes. It was reported that Tau was not contained in exosomes secreted by immature cortical neurons (DIV9) . We confirmed this for exosomes from young neurons (DIV 7-9) (data not shown) and therefore we focused on exosomes released by mature neurons (DIV14-21).
Exosomes in the conditioned medium of the cultured cortical neurons (DIV14-21) were isolated according to a published protocol  and lysed for western blot analysis. The isolated exosomes were enriched for Alix and Flotillin--- two well-accepted exosomal markers, as much higher amounts of these two proteins were detected in the exosomal lysates than in the cell lysates (Fig. 1a, lanes 3, 4). Tau was detected in exosomal lysates (Fig. 1a, lane 2), but, unlike Alix and Flotillin, Tau was not a major protein component of exosomes, since its level in exosomal lysates was dramatically lower than that in cell lysates (about 14 fold change, Fig. 1a, lanes 1, 2). The two Tau bands (Mr ~ 48 and 50kD) in the exosomal lysates were ~ 5kD smaller than the Tau bands (Mr ~ 54 and 56kD) in the cell lysates on SDS gels (Fig. 1a, lanes 1, 2). We suspected that this might be due to the cleavage of Tau at Asp421 by caspase 3 because such a truncation generates a Tau fragment ~ 5kD smaller than intact Tau . Thus, exosomal Tau was analyzed with an antibody specific for Tau truncated at Asp421, but no signal was detected (data not shown), suggesting that exosomal Tau is not truncated at this site. We quantified Tau in exosomes and in conditioned medium by ELISA. We found that the exosomal Tau accounts for ~2% of the total extracellular Tau (Fig. 1b), consistent with a previous report (~3% of extracellular Tau) .
It has been reported that Tau released by cultured neurons is hypophosphorylated . This prompted us to test whether exosomal Tau is also hypophosphorylated and thereby exhibits increased mobility on SDS gels compared to the cytosolic Tau. We examined the phosphorylation status of Tau with phosphorylation-dependent antibody PHF1 and AT8. In addition, we checked if dephosphorylation of neuronal Tau can reduce the Mr difference between neuronal and exosomal Tau. We treated neuronal lysates with alkaline phosphatase (AP) which resulted in a downward Mr shift of ~5kD (Fig. 1c, 1st panel, lanes 1, 2), to a similar level as exosomal Tau bands (Fig. 1c, 1st panel, lanes 2, 3). The loss of phosphorylation was confirmed by the disappearance of the PHF1 and AT8 reactivity (Additional file 1: Figure S1, lanes 1, 2 and 4, 5). Notably, PHF1 and AT8 did not detect Tau bands in exosomal lysates (Additional file 1: Figure S1, lanes 3, 6), indicating that they were not phosphorylated at these sites. Collectively, these results show that exosomal Tau is in a low state of phosphorylation compared to neuronal cytoplasmic Tau.
To further confirm that exosomal Tau is intact but not truncated, we probed Tau with antibody SA4470 (against N-terminal residues 1–17) and with antibody Tau C-ter (against C-terminal residues 400–441) (Fig. 1c, panel 2, 3). Both antibodies recognized exosomal Tau (Fig. 1c, lanes 6, 9), indicating that it is indeed intact.
To characterize the purified neuronal exosomes, we examined the size distribution using nanoparticle tracking analysis (NTA). The size distribution peaked around 75 nm (Fig. 1d), which is typical for exosomes, indicating their enrichment in the preparations. Another characteristic feature of exosomes is their density, ranging from 1.08 to 1.22 g/ml depending on their cellular origin . We fractionated exosomes on a sucrose gradient and examined the distribution of the exosomal markers Flotillin and Alix by western blotting. Both markers were enriched in fractions 5–8 at a density between ~1.16 to ~1.06 g/ml (Fig. 1e, upper panels), which fits well with the density of exosomes. Tau was enriched in fractions 7 and 8 overlapping with Flotillin and Alix (Fig. 1e, bottom panels), suggesting that the majority of Tau is associated with exosomes in these preparations. We assessed the morphology of the purified exosomes using electron microscopy and atomic force microscopy. EM showed that the vesicles were cup-shaped with a diameter of ~40–100 nm (Fig. 1f), consistent with the typical exosomal morphology . AFM confirmed that the majority of the vesicles have diameters around 40–100 nm (Additional file 2: Figure S2). The vesicles exhibited disk-like structures, which is consistent with exosomal morphology reported by other groups . We further analyzed isolated exosomes using cryo-electron tomography, which is known to preserve structures faithfully. This showed that vesicles exhibited a roughly spheroidal shape with diameters of 50 - 100 nm (Fig. 1g), which was in line with exosomal morphology. Collectively, these results demonstrate that Tau can be secreted by neurons via exosomes.
Upregulation of exosomal Tau release by neuronal activity
It has recently been reported that the release of endogenous Tau via non-exosomal pathways by primary neurons is a physiological process which is stimulated by neuronal activity . Interestingly, the release of exosomes by neurons is stimulated by neuronal activity as well . Thus, we examined whether stimulating neurons could lead to elevated release of exosomal Tau. Cultured neurons were depolarized with 25 mM KCl for 3 h, while the control cultures were incubated in the same medium containing only 5 mM KCl. We first examined whether depolarization of neurons caused neurotoxicity using the LDH release assay. The high KCl treatment did not increase LDH release (Fig. 2a), suggesting that the depolarization of neurons within the treatment timeframe was not neurotoxic. Next, we checked the amount of Tau and Alix in lysates of these neuronal cultures or exosomes derived from them. In the neuronal lysates, depolarization of neurons did not affect the levels of Tau and Alix (Fig. 2b, lanes 1, 2; Fig. 2c). However, in the exosomal lysates, depolarization of neurons increased both Tau and Alix levels by ~60% (Fig. 2b, lanes 3, 4; Fig. 2d). Since the elevation of Tau was proportional to the elevation of Alix (Fig. 2d), the increase of Tau in exosomal preparations can be taken to result from the increased release of exosomes, instead of selective accumulation of Tau in exosomes. In conclusion, chemical stimulation of neurons increases exosomal secretion, leading to higher release of exosomal Tau.
Tau is located inside exosomes
Although a fraction of extracellular Tau is released via exosomes, there is the question of its origin and topology with regard to the exosomal vesicles. For example, since some neuronal death occurs spontaneously during culturing, a concern is whether the exosomal Tau is in fact derived from dead neurons and only loosely attached to the exosomal surface. To clarify this, we treated neuron-derived exosomes with increasing amounts of NaCl (from 0.01 to 0.5 M) to detach Tau stuck on the exosomal outer membrane and checked its influence on Tau and exosomal markers Alix and HSC70 . NaCl treatment had little effect on levels of Alix and HSC70 (Fig. 3a, lower panels), nor on exosomal Tau (Fig. 3a, upper panel). This shows that Tau is not just loosely associated with the exosomal surface, but rather is an integral part of the exosomal vesicle.
To corroborate this finding, we performed a proteinase K protection assay to examine whether Tau is protected by the exosomal membrane. Saponin was used to permeabilize exosomes. The exosomal Tau level was unchanged by treatment with either saponin or proteinase K alone for 5 min (Fig. 3b, upper panel, lanes 1–3), but it was dramatically reduced by ~70% by treatment with proteinase K together with saponin that permeabilized exosomes (Fig. 3b, upper panel, lane 4). The extended treatments with either saponin or proteinase K alone for 1 h reduced exosomal Tau levels by ~50% (Fig. 3b, upper panel, lane 5–7), probably because during incubation, part of the exosomes became broken, leading to the digestion of the released Tau by proteases attached to the exosomal surface or proteinase K resp. Notably, the treatment with saponin and proteinase K for 1 h resulted in the complete digestion of Tau as no exosomal Tau was detected (Fig. 3b, upper panel, lane 8). Collectively, these data show that exosomal Tau is protected from digestion by proteinase K, indicating Tau is located within exosomes. Similarly, the bona fide intraluminal exosomal proteins Alix and HSC70 were protected from proteinase K digestion (Fig. 3b, middle and lower panels, lanes 3, 4, 7, 8).
Exosomes can mediate the neuron-to-neuron transmission of Tau
Since endogenous Tau can be released via exosomes, we next examined whether exosomes can act as carriers to mediate the transmission of Tau between cells. In order to directly monitor Tau-containing exosomes, we prepared exosomes from N2a cells transiently over-expressing human Tau tagged with GFP at the N-terminus (longest isoform in CNS, 2N4R or hTau40, for short TauGFP). Western blot analysis revealed that only intact TauGFP but not truncated TauGFP was detected in exosomal preparations (Fig. 4a, top panel), suggesting that all GFP positive exosomes should contain TauGFP. The TauGFP protein was confirmed by an anti-GFP antibody (Fig. 4a, middle panel). The exosomal preparations were validated by the enrichment of the exosomal marker Flotillin in comparison with the cell lysates (Fig. 4a, bottom panel). Nanoparticle tracking analysis showed that the exosome preparation mainly contained vesicles with a diameter of ~55–80 nm (typical for exosomes), indicating the enrichment of exosomes in the preparations (Fig. 4b). Cryo-electron tomography revealed that the vesicles exhibited a spheroidal shape with a diameter of 50 -100 nm (Fig. 4c), which is in line with exosomal morphology.
To investigate the neuron-to-neuron transmission of exosomal Tau, we took advantage of microfluidic devices (MFD). They allow the culture of two populations of neurons in two separate chambers connected by microgrooves, enabling the direct observation of the transfer of exosomal Tau from neurons on one side (somal side) to neurons on the other side (neuritic side) (Additional file 3: Figure S3, B, D). They also enable the selective treatment of cells on only one side by applying fluidic isolation via maintaining a flow of medium between the two sides (Additional file 3: Figure S3, B, D). One caveat is that the uptake of exosomes can occur both at the somatodendritic and axonal compartments of neurons . Thus even though exosomes were added to the somal side of the chamber, some neurons on the neuritic side projecting through microgrooves might obtain exosomes via direct axonal uptake, independently of the transfer of exosomes from neurons seeded on the somal side. To solve this issue, we seeded the 1st order neurons on the somal side two weeks earlier than the 2nd order neurons on the neuritic side, anticipating that the projections from the 1st order neurons occlude the microgrooves and thus eliminate axons and dendrites from the 2nd order neurons to project through microgrooves (Additional file 3: Figure S3). To test whether indeed only the 1st order neurons project through microgrooves, we selectively stained either the 1st order neurons on the somal side (Additional file 3: Figure S3, C) or the 2nd order neurons on the neuritic side (Additional file 3: Figure S3, A) with DiI and monitored the staining of cells by live imaging. When the 2nd order neurons were stained with DiI, the cell bodies of some of the 1st order neurons on the somal side were also positive for DiI, because their neurites projected through microgrooves into the neuritic side (arrowhead in Additional file 3: Figure S3, A). By contrast, when the 1st order neurons were stained with DiI, no cell bodies of the 2nd order neurons were positive for DiI, although neurites from the 1st order neurons that projected through microgrooves into the neuritic side were labeled by DiI (Additional file 3: Figure S3, C). These results confirm that only the 1st order neurons projected through microgrooves. Accordingly, when the 1st order neurons were treated with TauGFP exosomes, any TauGFP found in the neurites or cell bodies of the 2nd order neurons would indicate its transmission from the 1st order neurons.
Treatment of the 1st order neurons on the somal side at DIV25 with TauGFP exosomes resulted in the distribution of TauGFP puncta in microgrooves (Fig. 4d, left panels), indicating the uptake of TauGFP exosomes by the 1st order neurons on the somal side. In addition, in ~4% (4.3 ± 0.4%) of the 2nd order neurons (DIV11), the diffuse distribution of TauGFP and the accumulation of TauGFP puncta in cell bodies was observed (Fig. 4d, right panels), suggesting the transmission of TauGFP from the 1st order neurons to the 2nd order neurons. Notably, the TauGFP puncta in 2nd order neurons were positive for Flotillin staining (Fig. 4e). Such TauGFP puncta in 2nd order neurons may come from two sources: (1) TauGFP exosomes internalized by the 1st order neurons; (2) newly synthesized exosomes in the 1st order neurons which contain TauGFP released by the internalized exosomes. Thus, we sought to test whether TauGFP exosomes internalized by the 1st order neurons can be directly transmitted to the 2nd order neurons (option 1). To this end, we isolated exosomes from N2a cells co-transfected with FlotillinGFP and RFP-Tau (TauRFP). We utilized 3-chamber devices, as they allow the observation of the transmission of exosomes to an additional population of neurons in the 3rd chamber. We reasoned that if puncta in the 2nd or 3rd order neurons contain both TauRFP and FlotillinGFP, they would represent the exosomes internalized by the 1st order neurons, as it is unlikely that the newly synthesized exosomes in the 1st or 2nd order neurons encapsulate both TauRFP and FlotillinGFP released by the internalized exosomes. As shown in Fig. 4f, when the 1st order neurons were treated with TauRFP and FlotillinGFP exosomes, majority of puncta in the 2nd order neurons were positive for both TauRFP and FlotillinGFP. In addition, puncta containing TauRFP and FlotillinGFP were also observed in the 3rd order neurons. These results suggest that exosomes can indeed be directly transmitted between neurons.
Since recent studies have suggested that the spreading of Tau occurs by a trans-synaptic mechanism [8, 9, 44], we sought to determine whether and how the transmission of TauGFP exosomes can occur from the axons of the 1st order neurons to the 2nd order neurons. The microfluidic devices with short microgrooves (~150 μm) used in the above experiments allow axons and dendrites of the 1st order neurons to reach the neuritic side, enabling the potential transfer of TauGFP exosomes to 2nd order neurons. To distinguish between axons and dendrites, we performed experiments in microfluidic devices with long microgrooves (~900 μm) that prevent dendrites to project to the neuritic side. TauGFP puncta were detected in both microgrooves and 2nd order neurons (Fig. 4g), indicating that transmission of TauGFP can occur through axons.
Synaptic contacts are required for exosome-mediated transmission of Tau
We next determined how the TauGFP exosomes were transmitted from 1st order neurons to 2nd order neurons in microfluidic devices. Two possible mechanisms may explain the exosome-mediated transmission of Tau. (i) Transmission takes place specifically through trans-synaptic connections from 1st order to 2nd order neurons. (ii) Exosomes in 1st order neurons are released into the conditioned medium and then internalized by 2nd order neurons at extrasynaptic sites (Fig. 5a). We analyzed the formation of synapses in 2nd order neurons (DIV11) on the neuritic side by examining the co-localization of the post-synaptic marker GluR1 (green) and the pre-synaptic marker synaptophysin (red) (Fig. 5b). Mature synapses were observed in 2nd order neurons (DIV11) (Fig. 5, b3), although at a lower density than in mature neurons (DIV 25 or DIV18) on the somal side (Fig. 5, b1, b2, b5). Thus, synaptic contacts may contribute to TauGFP transmission in this case. To further determine the potential role of synaptic contacts in the transmission of Tau, we examined whether the transmission of TauGFP exosomes can occur when no synapses are present in 2nd order neurons. To this end, we selectively treated the 1st order neurons (DIV18) when the 2nd order neurons were at a very early stage (at DIV4). No synaptic contacts were detected in 2nd order neurons at DIV4 (Fig. 5, b4). Notably, no TauGFP puncta were detected in the cell bodies of the 2nd order neurons at DIV4 (before synapse formation, Fig. 5c, right panels), although TauGFP puncta in microgrooves were detected (Fig. 5c, left panels). This indicates that although TauGFP exosomes were taken up by the 1st order neurons on the somal side, they were not transmitted to 2nd order neurons. Taken together, these results suggest that synaptic contacts are necessary for the transmission of Tau by exosomes.
The low transmission of Tau into young neurons (DIV4) could be explained either because these neurons have not yet developed an uptake mechanism for exosomes, or because the TauGFP exosomes were not released on the neuritic side by the 1st order neurons. To clarify these alternatives we examined the uptake of exosomes by the young neurons (DIV4) and the release of the TauGFP exosomes on the neuritic side by neurites of 1st order neurons projecting through microgrooves using flow cytometry. To analyze the uptake of exosomes, young neurons (DIV4) or old neurons (DIV11) cultured in 24 well-plates were treated with purified TauGFP exosomes and the conditioned medium was collected for flow cytometry immediately after the addition of exosomes (Exo_0h) or 24 h later (Exo_24 h). After 24 h treatment, the amount of TauGFP exosomes in the conditioned medium was strongly reduced for both young neurons (DIV4) (down to 64.9 ± 12.7% of Exo_0h, Fig. 5e) and old neurons (DIV11) (to 57.3 ± 9.8% of Exo_0h, Fig. 5d), indicating that the uptake of TauGFP exosomes occurs at similar rate in both young (DIV4) and old (DIV11) neurons.
We further checked the uptake of TauGFP exosomes in young neurons (DIV4) by immunofluorescence assay. TauGFP exosomes were detected in neurons (arrows in Fig. 5f), indicating the internalization of exosomes. To determine the release of TauGFP exosomes by the neurites of the 1st order neurons on the neuritic side, conditioned medium on the somal and neuritic sides of the microfluidic chamber were collected for flow cytometry immediately after (Exo_0h) or 24 h after the addition of exosomes at the somal side (Exo_24 h). Nearly no TauGFP exosomes were detected in conditioned medium on the neuritic side after 24 h treatment of 1st order neurons on the somal side with TauGFP exosomes (Fig. 5g, h), regardless of the age of the 2nd order neurons (DIV4 or DIV11). This result suggests that once TauGFP exosomes were internalized by the 1st order neurons, they were rarely released into conditioned medium on the neuritic side by neurites of the 1st order neurons. Thus the transmission of TauGFP from the 1st order neurons to the 2nd order neurons (DIV11) occurs through synaptic contacts: TauGFP exosomes are released by presynapses and taken up by postsynapses.
To highlight the importance of synaptic connections for the transmission of Tau by exosomes, we performed another set of experiments using 3-chamber devices. When neurons were plated in all the three chambers, treatment of the neurons in the 1st chamber with TauGFP exosomes resulted in the distribution of TauGFP puncta in ~20% (20% ± 12.9%) of 2nd order neurons and ~4% (4.5 ± 0.5%) of 3rd order neurons. This suggests that TauGFP was transmitted (Fig. 5 i, j). However, when neurons were plated in the 1st and 3rd chambers, but not 2nd chambers (Additional file 4: Figure S4, A) (so that the axons from the two populations of neurons projected to the 2nd chamber), no synapses were formed between them. Treatment of the neurons in the 1st chamber with TauGFP exosomes resulted in the distribution of TauGFP puncta in microgrooves between 1st chamber and 2nd chamber (Additional file 4: Figure S4, B), indicating the uptake of TauGFP exosomes by neurons in the 1st chamber. However, no TauGFP exosomes were detected in microgrooves between the 2nd and 3rd chamber and in neurons in the 3rd chamber. This means that no transmission of TauGFP occurred between the two populations of neurons (Additional file 4: Figure S4, B). The results confirm that synaptic contacts are necessary for the transmission of Tau by exosomes.
Collectively, these data argue that exosomes can mediate the trans-synaptic transmission of Tau. Notably, when the 1st order neurons were treated with exosomes that were disrupted by sonication, no TauGFP puncta were detected in the microgrooves and the 2nd order neurons (data not shown), indicating that the integrity of exosomes is necessary for the transmission of Tau protein.
To exclude the possibility that the transmission of exosomal Tau between neurons is only applied to exosomes derived from N2a cells, we treated neurons in microfluidic devices with exosomes derived from neurons infected with adeno-virus expressing CFP-Tau40 (TauCFP). Similar to treatment with N2a cell-derived exosomes, CFP puncta were observed in the 2nd order neurons (Additional file 5: Figure S5B, right panels), suggesting exosomes can indeed serve as a carrier to regulate the transfer of Tau between neurons independently of the origin of exosomes.
We also tested the uptake of TauGFP exosomes in organotypic hippocampal slice cultures. As shown in Fig. 6a, we observed co-localization of TauGFP with the neuronal marker MAP2 (a1) and microglial marker Iba1 (a2, a3) but not with the astrocytic marker GFAP (a4), indicating TauGFP exosomes were preferentially internalized by neurons and microglia. Microglia are more competent in uptake of exosomes than neurons, as higher percentage of microglia (24.8 ± 14.1%) than neurons contained TauGFP exosomes (Fig. 6b). When the exosomes were disrupted by sonication, no uptake of TauGFP was observed (Additional file 6: Figure S6), consistent with the observation in primary neurons, indicating that exosomes need to be intact for internalization to occur.
The release of aggregation-prone Tau via exosomes by an N2a cell model of Tau aggregation
Several recent studies showed that pre-formed Tau aggregates can be taken up by cultured cells and subsequently induce local accumulation of other Tau molecules [14, 15]. We asked whether Tau aggregates can be encapsulated into exosomes and subsequently mediate the propagation of Tau aggregation. To this end, we made use of a cell model overexpressing the pro-aggregant 4-repeat domain of Tau with the mutation ΔK280 (TauRDΔK), since Tau forms aggregates in this cell model [30, 38].
We isolated exosomes from conditioned medium of this cell model and separated the soluble Tau and Tau aggregates using sarkosyl extraction. The sarkosyl extracts were used as controls. Consistent with our previous studies [38, 45], the sarkosyl-insoluble pellet from the cell lysates contained not only the protein TauRDΔK but also two smaller fragments (F2 and F3) which are generated by endoproteases and are required for nucleated aggregation (Fig. 7a). By contrast, the exosomal lysates contained only TauRDΔK, but fragments F2 or F3 are below detectability (Fig. 7a). In cell lysates, only ~3% of Tau was insoluble, while in exosomal extracts insoluble Tau was increased to ~12% (Fig. 7b). This result indicates that insoluble Tau is enriched in exosomes compared to cell lysates.
Since high speed centrifugation was used to isolate exosomes from the conditioned medium of N2a cells, this raises the question whether Tau aggregates detected in exosomal preparations actually represent the centrifugation-precipitated Tau aggregates derived from dead cells. To clarify this issue, we performed sucrose gradient centrifugation to fractionate the exosomal preparations and the sarkosyl insoluble pellet of the cell lysates, resp. and then examined whether Tau aggregates exhibit the same density as exosomes. For exosomal preparations, both exosomal marker Alix and Tau were only detected in fraction 4 with a density of ~1.19 g/ml (Fig. 7c). This is consistent with exosomal density (1.08 to 1.22 g/ml), indicating our preparations were enriched in exosomes. For the sarkosyl insoluble pellet of cell lysates, Tau was mainly found in fractions 1 and 9 (Fig. 7d, lower panel, lane 1, 9). The Tau in fraction 9 may be the soluble species that resulted from Tau aggregates, owing to the equilibrium between soluble and insoluble Tau. No Tau was detected in the exosomes-enriched fraction 4 (Fig. 7d, lower panel, lane 4). Of note, Alix was detected in fraction 4 (Fig. 7d, upper panel, lane 4), which might derive from intracellular vesicles contaminating the pellet of sarkosyl extraction. Collectively, these data indicate that the presence of TauRDΔK in exosomes is not due to the contamination of Tau aggregates in the exosomal preparation.
We further characterized isolated exosomes from N2a cells with nanoparticle tracking analysis, which showed that they mainly contained vesicles with a diameter of around 100 nm (typical for exosomes) (Fig. 7e). This was confirmed by AFM, which showed that the size of most of the vesicles was 40–100 nm (Fig. 7f). Finally, the isolated exosomes were analyzed with cryo-EM. The vesicles exhibited a spheroidal shape with a diameter of ~100 nm (Fig. 7g), which was consistent with exosomal morphology. Interestingly, materials of high density (indicated in blue, Fig. 7g, right lower panel) were detected in the vesicles. However, whether they represent Tau aggregates is not certain.
Exosomes derived from N2a cells expressing aggregation-prone TauRDΔK induce aggregation of full-length Tau in N2a cells
Given that exosomes derived from N2a cells expressing TauRDΔK contain insoluble Tau, we asked whether such exosomes could induce the aggregation of full-length Tau molecules in N2a cells. We previously reported that overexpressing aggregation-prone Tau fragments (e.g. fragment F3 = Tau258–360) can induce the aggregation of full-length Tau with the ΔK280 mutation (TauΔK280) [38, 45]. By analogy, we tested whether exosomes derived from N2a cells expressing TauRDΔK can induce the aggregation of hTauΔK. We monitored Tau aggregates using thioflavine S staining. The treatment by such exosomes indeed induced aggregation in N2a cells expressing TauΔK (~20-30/3-4X104 cells) (Fig. 7h, lower panel). Of note, treatment with sonicated exosomes failed to induce Tau aggregation (Fig. 7h, upper panel). These results demonstrate that exosomes can mediate the propagation of Tau aggregation.
Exosomes in CSF from AD patients and control subjects contain Tau and can induce Tau aggregation in cultured N2a cells
Given that Tau can be released by primary neurons via exosomes, we further searched for in vivo evidence of exosomal Tau. To this end, we isolated exosomes from the CSF of AD patients or control subjects (Table 1) and examined whether Tau was a component of such exosomes. The purification of exosomes by this method was validated with sucrose gradient centrifugation, revealing the presence of the exosomal marker protein Flotillin at a density of 1.16–1.24 g/ml  and electron microscopy . We first characterized the isolated exosomes using nanoparticle tracking. The size distributions of the particles showed maxima around 70–100 nm (Additional file 7: Figure S7), indicating that the preparations were indeed enriched in exosomes.
Western blot analysis with pan-Tau antibody K9JA revealed multiple bands between 53kD and 80kD in both AD and control exosomal preparations (Fig. 8, a1). A further band of ~180kD (arrowhead in Fig. 8, a1-a3) was detected in both AD and control exosomal preparations, indicating the presence of SDS-stable Tau oligomers in exosomes. To determine whether the Tau oligomers were selectively encapsulated into exosomes, we checked Tau in CSF before exosome isolation. Two Tau bands above 50kD and 60kD were detected, but no band around 180kD (Fig. 8b), suggesting that the Tau oligomers were enriched in exosomes, compared to the free CSF Tau. No significant differences in the levels of Tau was observed between exosomes from AD and from controls (Fig. 8, c1). Further analysis of Tau phosphorylation revealed that the ~180kD band (arrowhead in Fig. 8, c2, c3) and two other Tau bands (~53kD and ~68kD, arrows) were phosphorylated at the 12E8 and PHF1 sites (Fig. 8, c2, c3). This is in contrast to Tau in exosomes from cultured neurons which is hypophosphorylated based on the increased mobility during gel electrophoreses (Fig. 1c). No significant differences in the levels of Tau phosphorylated at 12E8 and PHF1 sites was detected between exosomes from AD and from controls (Fig. 8, c2, c3). Notably, multiple Tau bands between 53kD and 68kD (Fig. 8, a1, indicated by *) were not recognized by 12E8 and PHF1 antibodies (Fig. 8, a2, a3).
Taken together, these data suggest that both monomeric and oligomeric Tau phosphorylated at 12E8 and PHF1 sites as well as monomeric Tau unphosphorylated at 12E8 and PHF1 sites can be secreted via exosomes in vivo in human brains, and in both cases the Tau monomers or oligomers are encapsulated within the exosomes.
Recently, it was shown that exosomes from patients with Parkinson Disease (PD) and Dementia with Lewy Bodies (DLB) can induce α-synuclein aggregation . This prompted us to examine whether exosomes isolated from human CSF are able to seed Tau aggregation, since we showed above that these exosomes contain Tau oligomers (Fig. 8a), and that exosomes isolated from N2a cells expressing TauRDΔK can induce Tau aggregation (Fig. 7h). We took advantage of a split-luciferase fragment complementation technique to analyze whether exosomes from human CSF can promote TauRDΔK aggregation (Fig. 8d). Treatment with exosomes from AD or control CSF (Table 2) dramatically increased TauRDΔK aggregation, as they elevated the luminescence signal by ~50 and 40% respectively compared to control treated with PBS (Fig. 8e). Slightly higher aggregation was induced by exosomes from AD than exosomes from controls, but this did not reach statistical significance (Fig. 8e).
Tau pathology spreads in a hierarchical pattern in AD. It has been proposed that this can occur through the direct transfer of Tau between neurons through neuronal synaptic connections [8, 9], but the mechanism underlying this process remains elusive. Here, we demonstrate that exosomes can act as carriers to mediate the direct trans-synaptic transmission of Tau.
In cultured primary neurons, the secretion of Tau has been proposed to partly depend on pre-synaptic vesicle secretion , however, Tau is not found in the synaptic vesicle proteome . Other mechanisms thus must be involved in the secretion of Tau. Growing evidence suggests that Tau is released via an unconventional secretory pathway independent of the ER/Golgi mediated secretory pathway . This pathway includes 4 modes: direct translocation from the cytoplasm across the plasma membrane, release via secretory lysosomes, microvesicle shedding, or exosome release . It has been a matter of debate whether Tau is a component of exosomes, as some studies showed Tau to be present in exosomes from different cells including neurons [26, 48], whereas others did not find this [11, 12, 49]. Here, we show that Tau is indeed released via exosomes by cultured neurons, by N2a cells overexpressing human Tau and in vivo in human brain. The secretion of exosomal Tau by neurons is not an artifact due to the association with the exosomal surface by Tau protein from dead cells, because we find that Tau is located inside exosomes (Fig. 3). In addition, chemical stimulation of neurons increases secretion of exosomes containing Tau without obvious neurotoxicity (Fig. 2). This further argues that exosomal Tau release is a physiological process regulated by neuronal activity. The failure of some earlier studies to detect exosomal Tau may be explained as follows: (1) Only a small amount of exosomes isolated from limited starting material was used to detect Tau. Since Tau is not a major component of exosomes (Fig. 1a), and since only a small fraction of released Tau (~2%) is associated with exosomes (Fig. 1b), a robust amount of exosomes is necessary for the analysis of associated Tau. (2) Some cell types could encapsulate Tau into exosomes only poorly, as both biosynthesis of exosomes and their contents may vary between cells . It is worth noting that although we detect Tau in exosomes from mature neurons (DIV14-21), we found no Tau in exosomes from immature neurons (DIV9), consistent with another study . Thus, the Tau content of neuronal exosomes appears to be developmentally regulated and cell-type dependent.
We found that the Tau physiologically released via exosomes by cultured neurons was both intact and hypophosphorylated, compared with cytosolic Tau. It is not clear whether exosomes accumulate preferentially Tau in a low state of phosphorylation, or whether the ingested Tau is dephosphorylated by some exosomal phosphatase. It is worth noting that hypophosphorylated intact Tau was detected in conditioned medium of neuronal cultures in a previous study , although such extracellular Tau was demonstrated to be non-exosome associated, as Tau is barely detected in exosomal preparations, probably due to the limited material loaded. By contrast, another report stated that only C-terminally truncated Tau lacking the microtubule binding domain is released by cultured neurons or other types of cells  and a small fraction of extracellular Tau (<0.2%) is indeed present in exosomes. The cause of the discrepancy (truncated Tau v.s. intact Tau) between these papers is unknown. In addition, there has been a debate whether human CSF contains intact Tau or truncated Tau, but independently of that we observed intact Tau in CSF from AD and control subjects and also in exosomes derived from such CSF (Fig. 8a, c).
Pathological proteins or miRNAs in exosomes have emerged as potential biomarkers for AD and other neurodegenerative diseases [34, 51, 52]. A recent study demonstrated the presence of Tau in exosomes isolated from blood of patients with AD or frontotemporal dementia (FTD) and that the exosomal levels of total Tau and Tau phosphorylated at T181 or S396 for AD and FTD were significantly higher than in control subjects . We show here that Tau is present in exosomes from human CSF as well. However, distinct from blood-derived exosomes, there is no significant difference in the levels of Tau phosphorylated at 12E8 (pS262 + pS356) or PHF1 sites (pS396 + pS404) between CSF-derived exosomes from AD and control cases. In addition, the presence of Tau phosphorylated at 12E8 and PHF1 sites in CSF-derived exosomes is in contrast to the absence of such tau species in exosomes derived from cultured neurons.
Since Tau oligomers are considered the major toxic species in AD, it is of interest to know whether they occur in exosomes as well. We find that SDS-stable Tau oligomers were preferentially encapsulated into CSF-derived exosomes from AD and control cases (Fig. 8a). Consistent with our results, Saman et al. reported the identification of Tau oligomers in exosomes isolated from CSF of AD, but whether Tau oligomers are also present in exosomes from control subjects was not determined in that study . They found that the AD CSF-derived exosomes contained 35-40kD truncated Tau species and Tau trimers of ~105kD . This is different from what we identified here: the exosomal Tau from both AD and control CSFs consisted mainly of species of 55-68kD that likely represent intact Tau isoforms and Tau oligomers of ~180kD that might be trimers of intact Tau (Fig. 8a, c). The cause of the discrepancy between these two studies is unclear, but it may be related to the different preparations of CSF, as Saman et al. used postmortem CSF while we used freshly collected CSF. As Tau oligomers may be neurotoxic, the exosome-mediated release of Tau oligomers may actually be a protective process for neurons to clear these toxins, by analogy to the observation of exosome-mediated release of alpha-synuclein . However, on the other hand, we showed that such exosomes from human CSF promote tau aggregation (Fig. 8e), probably because the exosomal Tau oligomers can seed the aggregation of other Tau molecules, and thereby mediate the propagation of tau pathology.
Some recent studies proposed that Tau pathology can spread via a trans-synaptic pattern [8, 9, 44]. However, direct evidence showing transmission of Tau from presynaptic to postsynaptic compartments is still lacking. Microfluidic devices are excellent tools to study the transitions of Tau between cell compartments and across cells. By using these chambers, we found that Tau is transmitted between neurons via exosomes (Fig. 4). Importantly, we showed that part of the exosomes may be taken up as intact vesicles by the 1st order neurons and then released and internalized by the 2nd order neurons. Our results indicate that the uptake of exosomes does not necessarily mean the fusion of exosomes with the plasma membrane to allow the direct transfer of exosomal content to the cytosol. Consistent with our results it has been shown that exosomes are recruited as single vesicles to the cell cytosol, instead of fusing with plasma membrane, and after internalization, the majority of the internalized exosomes move toward lysosomal compartments . In addition, our results suggest that some internalized exosomes may be spared from this pathway, and can be released and taken up by other neurons.
Moreover, we showed that the exosome-mediated transmission of TauGFP requires synaptic connections between the 1st order neurons on the somal side and 2nd order neurons on the neuritic side. This view is based on three observations. (1) No exosomes were detected in conditioned medium on the neuritic side, indicating that the transition of TauGFP does not occur because exosomes of 1st order neurons are released into the conditioned medium and then internalized by 2nd order neurons at extrasynaptic sites (Fig. 5a, ii). (2) There is no transmission of TauGFP exosomes from the 1st order to the young 2nd order neurons (DIV4) on the neuritic side (which lack synaptic connections) (Fig. 5c), indicating that synaptic contacts are necessary for exosome-mediated Tau transmission. (3) In the 3-chamber microfluidic devices, transmission of TauGFP was observed from neurons in the 1st chamber to neurons in the 2nd and 3rd chamber (Fig. 5i). However, no transmission of TauGFP was observed from neurons in the 1st chamber to neurons in the 3rd chamber, when no neurons were seeded in the 2nd chamber (Additional file 4: Figure S4). In this case, the two populations of neurons do not form synaptic connections, which confirms that synaptic connections are necessary for the transmission of TauGFP. Our results argue that the trans-synaptic transmission of TauGFP occurs because exosomes are preferentially released at presynapses of the 1st order neurons and subsequently taken up by the postsynapses of the 2nd order neurons (Fig. 9). However, it should be pointed out that here it is the internalized exosomes added to the somal side that are preferentially released at pre-synaptic terminals on the neuritic side. By contrast, the fusion of multivesicular bodies with membranes in cell bodies and dendrites may result in the release of “endogenous” exosomes at these sites as well .
Our study showed that Tau aggregates are preferentially released via exosomes by an N2a cell model of Tau aggregation, as higher percentage of Tau is insoluble in exosomes than in N2a cells (Fig. 7a, b). In addition, we found that Tau oligomers are present in human CSF-derived exosomes (Fig. 8a). Importantly, we showed that the Tau-aggregates containing exosomes can induce Tau aggregation in cultured cells (Figs. 7h and 8e). Taken together, our study implies that exosomes could play a role in the spreading of Tau pathology. Notably, exosome-associated Tau aggregates appear to be more efficient in seeding Tau aggregation than the free Tau aggregates, since the broken exosomes failed to induce Tau aggregation. Thus, although exosomal Tau only accounts for a tiny portion of extracellular Tau, the contribution of exosomes in the spreading of Tau pathology may not be negligible. Indeed, this view is supported by a recent study showing that inhibition of exosome synthesis halts tau propagation in a mouse model . In fact, the preferential release of internalized exosomes at pre-synaptic terminals would naturally explain why Tau pathology spreads in a hierarchical pattern rather than in a proximity-dependent pattern. The scenario includes several steps: (1) Tau aggregates containing exosomes are released in one brain area and internalized by neighbouring neurons; (2) Internalized exosomes undergo axonal transport and finally are released only at pre-synaptic terminals. (3) The released exosomes are taken up by the synaptically connected neurons in another area and subsequently induce Tau aggregation in these neurons. Recent studies proposed that certain Tau aggregates can undergo direct trans-synaptic transmission [56, 57]. However, it is not clear whether such Tau aggregates can only be released at pre-synaptic terminals. If such Tau aggregates could be released along the axon shaft, one would expect the occurrence of the proximity-dependent spreading of Tau pathology, unless other mechanisms exist that prevent the uptake of such Tau aggregates by surrounding neurons.
Recently, passive immunotherapies with Tau specific antibodies have been reported to retard the progress of Tau pathology in Tau transgenic mice. It has been proposed that Tau antibodies might achieve therapeutic effects by capturing extracellular Tau seeds and thereby prevent the seeding and trans-cellular propagation of Tau pathology [58–60]. However, given that exosomes shielding the contained Tau aggregates from recognition by antibodies may mediate the propagation of Tau aggregation, there is the question whether antibodies targeting only extracellular Tau can indeed terminate the progression of Tau pathology.
Finally, we found that exosomes are internalized by neurons and microglia but not by astrocytes in cultured organotypic hippocampal slices. Microglia are more efficient than neurons in uptake of exosomes. To date, whether or not extracellular vesicles including exosomes uptake is a cell type-specific process remains a matter of debate . A previous report showed that oligodendrocytes-derived exosomes are predominantly internalized by microglia via micropinocytosis, but not by neurons and astrocytes . The inconsistence between this study and our study may be related to the different origins of exosomes (N2a cells v.s. oligodendrocytes). The significance of the preferential internalization of exosomes by microglia over neurons requires further investigation.
Our data demonstrate that different Tau species including monomers, oligomers and aggregates may be released via exosomes by neurons or cultured cells. The Tau aggregates-containing exosomes derived from human CSF or cultured cells can promote Tau aggregation. Release of exosomes is enhanced by neuronal activity. Exosomes are involved in the trans-synaptic transmission of Tau between neurons and thus may contribute to the spreading of Tau pathology.
Atomic force microscopy
Bovine serum albumin
Days in vitro
Fetal bovine serum
Familial frontotemporal dementia and parkinsonism linked to chromosome17
Heat Shock Cognate Protein 70
Nanoparticle tracking analysis
- TauGFP :
Human longest isoform of brain Tau tagged with GFP at the N-terminus
- TauRDΔK :
Four-repeat domain of Tau with the mutation ΔK280
Transmission electron microscopy
Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2:a006247.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.
Braak H, Del Tredici K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 2011;121:171–81.
Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92:197–201.
Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med. 2013;62:90–101.
Fruhbeis C, Frohlich D, Kuo WP, Amphornrat J, Thilemann S, Saab AS, Kirchhoff F, Mobius W, Goebbels S, Nave KA, et al. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol. 2013;11:e1001604.
Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168–70.
Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302.
de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, et al. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron. 2012;73:685–97.
Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31:13110–7.
Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389–94.
Karch CM, Jeng AT, Goate AM. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J Biol Chem. 2012;287:42751–62.
Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgraefe K, Mandelkow E-M, Holtzman DM. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211:387–93.
Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845–52.
Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011;286:15317–31.
Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M, Kayed R, Zurzolo C, et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem. 2013;288:1856–70.
Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909–13.
Mohamed NV, Herrou T, Plouffe V, Piperno N, Leclerc N. Spreading of tau pathology in Alzheimer’s disease by cell-to-cell transmission. Eur J Neurosci. 2013;37:1939–48.
Chivet M, Javalet C, Hemming F, Pernet-Gallay K, Laulagnier K, Fraboulet S, Sadoul R. Exosomes as a novel way of interneuronal communication. Biochem Soc Trans. 2013;41:241–4.
Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, Dingli F, Loew D, Tkach M, Thery C. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016;113:E968–77.
Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol. 2004;16:415–21.
Korkut C, Li Y, Koles K, Brewer C, Ashley J, Yoshihara M, Budnik V. Regulation of postsynaptic retrograde signaling by presynaptic exosome release. Neuron. 2013;77:1039–46.
Kunadt M, Eckermann K, Stuendl A, Gong J, Russo B, Strauss K, Rai S, Kugler S, Falomir Lockhart L, Schwalbe M, et al. Extracellular vesicle sorting of alpha-Synuclein is regulated by sumoylation. Acta Neuropathol. 2015;129:695–713.
Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172–7.
Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, Laude H, Raposo G. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A. 2004;101:9683–8.
Simon D, Garcia-Garcia E, Gomez-Ramos A, Falcon-Perez JM, Diaz-Hernandez M, Hernandez F, Avila J. Tau overexpression results in its secretion via membrane vesicles. Neurodegener Dis. 2012;10:73–5.
Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012;586:47–54.
Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, Jackson B, McKee AC, Alvarez VE, Lee NC, Hall GF. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012;287:3842–9.
Faure J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, et al. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 2006;31:642–8.
Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281:1205–14.
Messing L, Decker JM, Joseph M, Mandelkow E, Mandelkow EM. Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors. Neurobiol Aging. 2013;34:1343–54.
Thery C, Amigorena S, Raposo G, Clayton A: Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006, Chapter 3:Unit 3 22.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.
Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A. Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies. Brain. 2016;139:481–94.
Mastronarde DN. Automated electron microscope tomography using robust prediction of specimen movements. J Struct Biol. 2005;152:36–51.
Gunkel M, Schoneberg J, Alkhaldi W, Irsen S, Noe F, Kaupp UB, Al-Amoudi A. Higher-order architecture of rhodopsin in intact photoreceptors and its implication for phototransduction kinetics. Structure. 2015;23:628–38.
Mastronarde DN. Dual-axis tomography: an approach with alignment methods that preserve resolution. J Struct Biol. 1997;120:343–52.
Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A. 2007;104:10252–7.
Lachenal G, Pernet-Gallay K, Chivet M, Hemming FJ, Belly A, Bodon G, Blot B, Haase G, Goldberg Y, Sadoul R. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci. 2011;46:409–18.
Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2003;100:10032–7.
Dujardin S, Begard S, Caillierez R, Lachaud C, Delattre L, Carrier S, Loyens A, Galas MC, Bousset L, Melki R, et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One. 2014;9:e100760.
Palanisamy V, Sharma S, Deshpande A, Zhou H, Gimzewski J, Wong DT. Nanostructural and transcriptomic analyses of human saliva derived exosomes. PLoS One. 2010;5:e8577.
Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21:R125–34.
Dujardin S, Lecolle K, Caillierez R, Begard S, Zommer N, Lachaud C, Carrier S, Dufour N, Auregan G, Winderickx J, et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun. 2014;2:14.
Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18:4153–70.
Takamori S, Holt M, Stenius K, Lemke EA, Gronborg M, Riedel D, Urlaub H, Schenck S, Brugger B, Ringler P, et al. Molecular anatomy of a trafficking organelle. Cell. 2006;127:831–46.
Nickel W and Rabouille C. Mechanisms of regulated unconventional protein secretion.Nat Rev Mol Cell Biol. 2009;10(2):148–55.
Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF. Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis. 2010;19:647–64.
Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem. 2012;287:20522–33.
Kanmert D, Cantlon A, Muratore CR, Jin M, O’Malley TT, Lee G, Young-Pearse TL, Selkoe DJ, Walsh DM. C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death. J Neurosci. 2015;35:10851–65.
Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ. Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement. 2015;11:600–7. e601.
Lugli G, Cohen AM, Bennett DA, Shah RC, Fields CJ, Hernandez AG, Smalheiser NR. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One. 2015;10:e0139233.
Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42.
Heusermann W, Hean J, Trojer D, Steib E, von Bueren S, Graff-Meyer A, Genoud C, Martin K, Pizzato N, Voshol J, et al. Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER. J Cell Biol. 2016;213:173–84.
Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kugler S, Ikezu T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584–93.
Calafate S, Buist A, Miskiewicz K, Vijayan V, Daneels G, de Strooper B, de Wit J, Verstreken P, Moechars D. Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. Cell Rep. 2015;11:1176–83.
Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, Nicholls SB, Carlson GA, Pitstick R, Nobuhara CK, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain. Nat Commun. 2015;6:8490.
d'Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One. 2013;8:e62402.
Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34:4260–72.
Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402–14.
Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles 2014, 3. doi: 10.3402/jev.v3.24641
Fitzner D, Schnaars M, van Rossum D, Krishnamoorthy G, Dibaj P, Bakhti M, Regen T, Hanisch UK, Simons M. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J Cell Sci. 2011;124:447–58.
The authors thank Dr. J. Biernat (DZNE Bonn) for the generation of inducible N2a cell models and plasmids expressing different Tau constructs; J. Roth and J. Luedtke for preparing primary neurons; M. Kunadt (Univ. Göttingen), and C. Tröger (CAESAR, Bonn) for help with the plunge-freezing of samples for cryo-EM. We thank Dr. P. Seubert (Elan Pharma, South San Francisco, CA, USA) for antibody 12E8 and Dr. P. Davies (Albert Einstein College, New York) for PHF1 antibody.
This work was supported by DZNE, MPG, Tau Consortium, and Cure Alzheimer Fundation (to EM and EMM). AS was funded by the German Research foundation Cluster of Excellence “Nanoscale Microscopy and Molecular Physiology of the Brain” (CNMPB) and the Center for Molecular Physiology of the Brain (CMPB). AS received funding by the German Research Foundation (Deutsche Forschungsgemeinschaft) grant SCHN1265 1-1.
Availability of data and materials
Supplemental files are made available online along with the manuscript.
YW performed exosome isolation, biochemical experiments and immunofluorescence assays in N2a cells, as well as analysis, experimental design, writing of the manuscript and figure artwork. VB contributed neuron culture and immunofluorescence assay using microfluidic chambers, as well as analysis and figure artwork. SK performed AFM and FACS experiments. LK performed experiments using organotypic slices. RC characterized Tau antibody Tau C-ter. SI and KT performed cryo-EM experiments and analysis. AS and WM contributed human CSF samples and exosomes from human CSF. EM and E-MM supervised the study and writing of the manuscript. All authors revised the article critically for intellectual content and have read and approved the final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
All authors have given their consent for publication. Written informed consent was obtained from the participant for publication of their individual details and accompanying images in this manuscript. The consent form is held by the authors’ institution and is available for review by the Editor-in-Chief.
Ethics approval and consent to participate
All research involving the animals has been approved by Ethics Committee for animal research (LANUV, Recklinghausen, NRW, Germany), and is in line with the European and German regulations for animal research. Human subjects consent to participate is not applicable. Written informed consent was obtained from the patients for publication of their individual details and accompanying images in this manuscript. The consent form is held by the authors’ institution (IRB 02/05/09) and is available for review by the Editor-in-Chief.
Tau in exosomes from cortical neurons is not phosphorylated at PHF1 and AT8 sites. Tau in neuronal lysates is phosphorylated at PHF1 and AT8 sites (lanes 1, 4), whereas Tau in dephosphorylated neuronal lysates and exosomal Tau are not detectably phosphorylated at these sites (lane 2, 3 and 5, 6). (PNG 30 kb)
Atomic force microscopy of exosomes from cortical neurons. (A) The amplitude, height and 3D images of AFM. Scale bar = 100 nm. (B) Quantification of the size of exosomes. The majority of the vesicles are 40–100 nm. (PNG 89 kb)
Projections of neurons cultured in microfluidic devices with short microgrooves (150 μm). The 1st order hippocampal neurons were seeded on the somal side (left) of the microfluidic chamber. Fourteen days later, the 2nd order hippocampal neurons were seeded on the neuritic side (right) and cultured for additional 10–11 days. Neurons were treated on the neuritic side (A) or somal side (C) with DiI for 2 to 3 h. The living cells were then imaged using fluorescence microscopy. Scale bar = 10 μm. When the 2nd order neurons on the neuritic side were treated with DiI (A, top right panel), cell bodies of the 1st order neurons whose neurites projected through microgrooves to the neuritic side were positive for DiI staining (arrowhead in A, top left panel), by contrast, cell bodies of neurons that do not project to the neuritic side were not positive for DiI staining (arrows in A, bottom left panel). When the 1st order neurons on the somal side were treated with DiI (C, top left panel), their processes that projected through microgrooves to the neuritic side were stained by DiI (C, top right panel). However, no cell bodies of the 2nd order neurons (arrows in C, bottom right) were positive for DiI staining, indicating that the 2nd order neurons do not project through microgrooves to the somal side. The result of A and C is illustrated by B and D resp.. The flow of the conditioned medium (indicated by arrow) prevents the diffusion of added Dil from treated side to the opposite side. (PNG 175 kb)
No transmission of TauGFP exosomes from 1st order neurons in the first chamber to the 2nd order neurons in the third chamber. (A) Diagram to show the culture of neurons in 3-chamber microfluidic devices. Neurons were seeded in the 1st and 3rd chambers at the same time, but not in the 2nd chamber. (B) No transmission of TauGFP exosomes from neurons (DIV10) cultured in 1st chamber to neurons cultured in 3rd chamber. The 1st order neurons cultured in the 1st chamber were treated with TauGFP exosomes (20 μg) at DIV10 for 24 h. Neurons were stained with an antibody against tubulin (red). Arrows indicate TauGFP positive exosomes in the first channel and in the axons projecting from the 1st order neurons. Note the absence of TauGFP positive exosomes in the third channel indicating no transmission of TauGFP via exosomes between the two populations of neurons. Scale bar = 10 μm. (PNG 118 kb)
Uptake and transmission of TauCFP by neurons cultured in microfluidic chambers via exosomes derived from cultured neurons. (A) Nanoparticle tracking analysis of exosomes derived from primary neurons transfected with TauCFP. The size distribution peaks at ~90 nm, indicating the enrichment of exosomes in the preparations. (B) Uptake and transmission of exosomes containing TauCFP isolated as in (A) by neurons cultured in microfluidic chambers with long microgrooves (900 nm). The 1st order neurons at DIV25 were treated for 24 h with exosomes (20 μg) isolated from primary cortical neurons infected with adeno-virus expressing TauCFP, when the 2nd order neurons were at DIV11. Neurons were then fixed and stained for immunofluorescence microscopy with antibodies against MAP2 (red). Arrows denote TauCFP exosomes. Scale bar = 10 μm. Note that TauCFP exosomes were detected in the 2nd order neurons on the neuritic side, indicating their uptake by 1st order neurons on the somal side, transport across the microgrooves, and synaptic transmission to the neurons on the neuritic side. (PNG 157 kb)
No uptake of sonicated exosomes derived from N2a cells expressing TauGFP by neurons or astrocytes in organotypic hippocampal slices. Hippocampal slice cultures were incubated for 24 h with sonicated exosomes (20 μg) derived from N2a cells expressing TauGFP. Cultures were then stained for neuronal marker MAP2 (red) and astrocytic marker GFAP (blue) in hippocampal CA1 region. No TauGFP was observed in slices. Scale bars in upper panel = 20 μm; in bottom panel = 5 μm. (PNG 191 kb)
Nanoparticle tracking analysis of exosomes isolated from CSF of control (A) and AD subjects (B) showing particle number vs. size (arbitrary units, peak = 100%). The size distributions have peaks at diameters of ~85–100 nm (AD) or ~60–90 nm (non-AD controls). (PNG 29 kb)